1. Home
  2. BGI vs NXL Comparison

BGI vs NXL Comparison

Compare BGI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birks Group Inc.

BGI

Birks Group Inc.

HOLD

Current Price

$1.04

Market Cap

22.7M

Sector

N/A

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.85

Market Cap

18.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGI
NXL
Founded
1879
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.7M
18.6M
IPO Year
2005
2022

Fundamental Metrics

Financial Performance
Metric
BGI
NXL
Price
$1.04
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
28.0K
113.8K
Earning Date
12-05-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$136,846,182.00
$156,931.00
Revenue This Year
N/A
$38.28
Revenue Next Year
N/A
$185.71
P/E Ratio
N/A
N/A
Revenue Growth
7.45
N/A
52 Week Low
$0.56
$0.70
52 Week High
$2.03
$4.19

Technical Indicators

Market Signals
Indicator
BGI
NXL
Relative Strength Index (RSI) 36.09 32.08
Support Level $1.00 $0.93
Resistance Level $1.09 $1.01
Average True Range (ATR) 0.05 0.06
MACD -0.01 -0.00
Stochastic Oscillator 20.32 6.84

Price Performance

Historical Comparison
BGI
NXL

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: